Eisai Co Ltd
Change company Symbol lookup
Select an option...
ESALY Eisai Co Ltd
CNX CNX Resources Corp
WW WW International Inc
IBM International Business Machines Corp
NEP Nextera Energy Partners LP
TMP Tompkins Financial Corp
MFM MFS Municipal Income Trust
GPX GP Strategies Corp
AMH-E American Homes 4 Rent

Health Care : Pharmaceuticals | Large Cap Blend
Based in Japan
Company profile

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
-0.34 (-0.43%)
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: Facebook chief marketing officer to depart in September

4:47 pm ET August 21, 2020 (MarketWatch)

Facebook Inc. (FB) shares were flat in after-hours trading Friday following the company's announcement that its chief marketing officer, Antonio Lucio, is leaving Sept. 18. A company spokesman said Lucio, who joined Facebook in 2018 from HP Inc. (HPQ), is leaving to dedicate his time to diversity, inclusion and equity. During Lucio's tenure at Facebook, the social-networking company increased worldwide ad spending to rebuild trust as it grappled with barbs about its privacy practices and how it handles misinformation on its digital platforms. "Antonio did incredible work telling our story during a transformative period for the company. We're grateful for his enormous contributions and wish him well in his next chapter," a company spokesman said in a statement. Facebook's stock is up 30% in 2020. The broader S&P 500 index is up 5% this year.

-Jon Swartz; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 21, 2020 16:47 ET (20:47 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.